Rahul Kota | Cancer Genetics | Young Scientist Award

Published on by Oncology

Young Scientist Award

Rahul Kota
QIS College of Pharmacy, India

Rahul Kota
Affiliation QIS College of Pharmacy
Country India
Subject Area Cancer Genetics
Event International Research Awards on Oncology and Cancer Research
ORCID 0009-0007-0528-4865

Rahul Kota is affiliated with QIS College of Pharmacy in India and is identified with the subject area of cancer genetics. Cancer genetics examines the relationship between genetic variation, genomic alterations, inherited susceptibility, and the development or progression of cancer. The field contributes to understanding molecular mechanisms of disease and can support the development of improved approaches to cancer risk assessment, diagnosis, classification, and treatment. [1]

Abstract

This academic recognition profile concerns Rahul Kota of QIS College of Pharmacy, India, whose stated subject area is Cancer Genetics. Cancer genetics is an interdisciplinary area within biomedical and oncology research that investigates genetic and genomic factors associated with cancer initiation, susceptibility, progression, and therapeutic response. Modern cancer research increasingly integrates molecular genetics with genomic technologies to characterize tumor biology and identify clinically relevant alterations. [1]

Keywords

Cancer Genetics; cancer genomics; oncology research; genetic variation; tumor genetics; molecular oncology; genomic medicine; cancer susceptibility; precision oncology; biomedical research; young scientist; cancer research.

Introduction

Cancer is fundamentally a disease involving alterations to cellular genetic and regulatory processes. Genetic changes may arise through inherited variation or accumulate during an individual’s lifetime, with combinations of genomic alterations influencing tumor development and biological behavior. Large-scale genomic studies have demonstrated substantial molecular diversity among cancers, supporting the classification of tumors according to their underlying molecular characteristics. [2]

Research Profile

Rahul Kota is associated with QIS College of Pharmacy and has been identified for this profile under the research area of Cancer Genetics. The supplied researcher identifier is ORCID 0009-0007-0528-4865, providing a persistent digital identifier that can be used to distinguish a researcher from other individuals with similar names.

Research Contributions

Within cancer genetics, research contributions may encompass investigation of inherited and acquired genetic alterations, molecular mechanisms of tumor development, genetic determinants of cancer susceptibility, genomic characterization of tumors, and the interpretation of molecular information for oncology applications. Cancer-associated genetic alterations can affect pathways involved in cell proliferation, DNA repair, apoptosis, and other processes relevant to malignant transformation. [3]

Publications

No verified publication list was supplied for this profile. Consequently, individual publications, journal articles, citation counts, and DOI records are not attributed to Rahul Kota in order to avoid conflating publications by researchers with similar names.For a formal academic evaluation, publications should be verified through authoritative scholarly records and matched using persistent identifiers, institutional affiliation, subject area, authorship information, and DOI metadata where available.

Research Impact

Cancer genetics has substantial relevance to contemporary oncology because genomic information can improve understanding of disease heterogeneity and provide a foundation for molecularly informed clinical research. The identification and interpretation of cancer-associated alterations have become important components of translational oncology and precision-medicine research. [2] [3]

Award Suitability

The Young Scientist Award is presented here within the context of the International Research Awards on Oncology and Cancer Research. Rahul Kota’s supplied affiliation with QIS College of Pharmacy and stated specialization in Cancer Genetics establish a subject-area connection with oncology and cancer research.Based solely on the supplied information, the profile demonstrates thematic alignment with the award’s oncology research scope. A complete award assessment would additionally require verification of eligibility criteria, research outputs, publication record, originality of contributions, and other evaluation requirements established by the award program.

Conclusion

Rahul Kota, affiliated with QIS College of Pharmacy in India, is profiled within the field of Cancer Genetics for consideration under the Young Scientist Award associated with the International Research Awards on Oncology and Cancer Research. The available information supports a clear subject-area relationship with oncology research. Further assessment of scholarly achievement should be based on verified publication, citation, authorship, and research-impact evidence.

References

1. Hanahan, D. (2022). Hallmarks of Cancer: New Dimensions. Cancer Discovery, 12(1), 31–46.
        https://doi.org/10.1158/2159-8290.CD-21-1059

2. The Cancer Genome Atlas Research Network. (2013). The Cancer Genome Atlas Pan-Cancer analysis project. Nature Genetics, 45, 1113–  1120.                         https://doi.org/10.1038/ng.2764

3. National Cancer Institute. (n.d.). Precision Medicine in Cancer. National Institutes of Health.
         https://www.cancer.gov/research/infrastructure/precision-medicine

4. Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., Jr., & Kinzler, K. W. (2013). Cancer Genome Landscapes. Science, 339(6127),          1546–1558.
         https://doi.org/10.1126/science.1235122

5. ORCID. (n.d.). ORCID: Connecting Research and Researchers.
          https://orcid.org/

Yasir Al-Mawlah | Cancer Genetics | Editorial Board Member

Published on by Oncology

Assist Prof Dr. Yasir Al-Mawlah | Cancer Genetics | Editorial Board Member 

Researcher | University Of Babylon | Iraq

Yasir Haider Al-Mawlah is an accomplished oncology- and biotechnology-oriented researcher and academic based at the DNA Research Center, University of Babylon, Iraq, with a strong interdisciplinary background spanning molecular biology, biotechnology, forensic genetics, and cancer-related research. He holds a verified academic appointment at the University of Babylon and has established a solid scientific profile with more than 220 citations, an h-index of 9, and an i10-index of 8, reflecting consistent scholarly impact over several years. His oncology-related work focuses primarily on molecular mechanisms of cancer development, genetic susceptibility, and biomarker discovery, particularly in breast cancer. He has contributed significantly to studies examining genetic polymorphisms in antioxidant enzymes such as SOD, CAT, and GPx1 and their association with breast cancer risk, oxidative stress, and biomarker alterations, providing insights into cancer pathogenesis and potential diagnostic indicators. In addition, his research includes anti-cancer evaluations of natural compounds, such as plant-derived alkaloids, against human breast cancer cell lines, highlighting translational approaches that bridge natural product research and oncology therapeutics. Beyond cancer, his scientific contributions extend to microRNA expression profiling, including fertility, forensic identification, and body fluid differentiation, demonstrating advanced expertise in non-coding RNA stability and specificity. He has also published widely on antimicrobial nanoparticles, nanobiotechnology, and multidrug-resistant pathogens, reflecting a broader biomedical scope relevant to cancer-associated infections and clinical complications. Dr. Al-Mawlah collaborates extensively with multidisciplinary teams across medical microbiology, genetics, pharmacology, and clinical sciences, both within Iraq and internationally. His publication record in peer-reviewed journals, combined with sustained citation performance, underscores his role as an active contributor to contemporary biomedical and oncology-related research, with work that supports early diagnosis, molecular risk assessment, and innovative therapeutic exploration in cancer and related diseases.

Profile: Google Scholar 

Featured Publications

Al-Mawlah, Y. H., Al-Darraji, M. N., & Al-Imari, M. J. (2022). Study of small non-coding RNA (miRNA) expression pattern of fertile/infertile male semen. Acta Informatica Medica, 30(3), 205–210.

Abdulazeem, L., Al-Alaq, F. T., Alrubaei, H. A., Al-Mawlah, Y. H., & Alwan, W. K. (2018). Anti-cancer activity of Opuntia polyacantha alkaloid extract on human breast cancer cell line. Journal of Pharmaceutical Sciences and Research, 10(7), 1753–1754.

Al-Mawlah, Y. H., Alasadi, Y. F., & Al-Darraji, M. N. (2021). Association between genetic polymorphisms of Cu/ZnSOD and CAT C262T and the risk of breast cancer. Gene Reports, 25, 101401.

Abdulazeem, L., Al-Amiedi, B. H., Alrubaei, H. A., & Al-Mawlah, Y. H. (2019). Titanium dioxide nanoparticles as antibacterial agents against some pathogenic bacteria. Drug Invention Today, 12(5), 963–967.

Al-Mawlah, Y. H., Naji, M. Z., Al-Imari, M. J., & Abdulabbas, H. S. (2022). Micro-RNA evaluation, specification, and stabilization study in mixed and non-mixed body fluids as a specific molecular marker. Journal of Advanced Biotechnology and Experimental Therapeutics, 5(2), 347–357.

Through integrative research in oncology, molecular genetics, and biotechnology, the nominee advances scientific understanding of cancer risk, biomarker discovery, and molecular diagnostics. His work bridges fundamental research with applied innovation, supporting early detection, personalized medicine, and translational solutions that benefit public health and biomedical development.